Goldman Sachs’s West Pharmaceutical WST Stock Holding History

Goldman Sachs’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40,000	Closed	-$9.09M	–	5560
2020 Q2	$9.09M	Hold	40,000	–	–	﹤0.01%	2347
2020 Q1	$6.09M	Sell	40,000 -5,000	-11%	-$770K	﹤0.01%	2487
2019 Q4	$6.76M	Buy	+45,000	New	+$6.55M	﹤0.01%	2725
2014 Q1	–	Sell	-2,200	Closed	-$108K	–	6954
2013 Q4	$108K	Buy	+2,200	New	+$103K	﹤0.01%	6250

Other funds holding WST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's WST Position: Q1 2026 in Review

Goldman Sachs increased its West Pharmaceutical (WST) stake by 65% in Q1 2026, buying an estimated $71.6M and bringing the position to 727,617 shares worth $182M. The position accounts for 0.02% of the portfolio, ranked #717.

Goldman Sachs first reported a position in WST in Q2 2013 and has held it in 52 quarters since. The position peaked at $367M in Q3 2020. 754 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Goldman Sachs held 727,617 shares of West Pharmaceutical worth $182M as of Q1 2026.
Goldman Sachs bought 287,572 West Pharmaceutical shares in Q1 2026, an estimated $71.6M.
West Pharmaceutical made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #717 holding.
Goldman Sachs first reported a position in West Pharmaceutical in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's West Pharmaceutical position peaked at $367M in Q3 2020.
754 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.